Intervacc AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVACC.ST research report →
Companywww.intervacc.se
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles.
- CEO
- Carl-Johan Dalsgaard
- IPO
- 2017
- Employees
- 15
- HQ
- Hägersten, SE
Price Chart
Valuation
- Market Cap
- $402.84M
- P/E
- -4.51
- P/S
- 21.33
- P/B
- 1.59
- EV/EBITDA
- -3.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -391.26%
- Op Margin
- -495.78%
- Net Margin
- -473.17%
- ROE
- -30.73%
- ROIC
- -36.93%
Growth & Income
- Revenue
- $20.09M · 70.42%
- Net Income
- $-80,815,000 · -7.02%
- EPS
- $-0.27 · 68.60%
- Op Income
- $-84,858,000
- FCF YoY
- -24.15%
Performance & Tape
- 52W High
- $1.46
- 52W Low
- $0.57
- 50D MA
- $1.01
- 200D MA
- $0.96
- Beta
- -0.27
- Avg Volume
- 614.65K
Get TickerSpark's AI analysis on IVACC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IVACC.ST Coverage
We haven't published any research on IVACC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IVACC.ST Report →